What Is NeuVax? Definition and What Research Reports

Definition

NeuVax is the clinical-trial trade name for nelipepimut-S, a peptide also referred to in the literature as E75, described in a 2014 review as a HER2-derived, HLA-A2/A3-restricted immunogenic peptide vaccine studied in breast cancer patients at risk for recurrence and administered together with granulocyte-macrophage colony-stimulating factor (GM-CSF) as an immunoadjuvant (PMID 24896623). In other words, the term does not describe a metabolic or performance peptide: it names a cancer-vaccine candidate built around a fragment of the HER2 protein, and it appears in the oncology literature almost exclusively in that context.

What Class of Molecule It Is and Where It Comes From

Nelipepimut-S belongs to the class of antigenic peptide vaccines rather than the class of receptor agonists or secretagogues. The sequence is taken from HER2 (human epidermal growth factor receptor 2), a protein overexpressed in a subset of breast cancers, and the 2014 review characterised E75 as an immunogenic HER2 peptide restricted to the HLA-A2 and HLA-A3 tissue types, meaning only patients carrying those HLA alleles were eligible in the trials it summarised (PMID 24896623).

The general mechanism attributed to this class in a 2015 review of peptide vaccines in breast cancer is presentation of the short peptide on major histocompatibility complex molecules so that peptide-specific cytotoxic T lymphocytes can be expanded and directed against tumour cells expressing the parent protein (PMID 26523780). Because a naked short peptide is weakly immunogenic on its own, trials of E75 paired it with GM-CSF, as the 2014 review described (PMID 24896623).

How the Term Is Used in Peptide Research

Readers encounter several names for the same agent. The table below maps the terminology as it appears in the cited literature.

In practice, a paper that says "E75" and a paper that says "NeuVax" are usually discussing the same peptide antigen; the choice reflects the era and the setting of the report. The term is used as a proper noun for a specific investigational product, not as a category label for HER2 peptides in general.

What the Published Literature Reports

The clearest summary of the early clinical work comes from the 2014 review, in which researchers reported that phase I and phase II testing of the HER2 peptide vaccine in breast cancer patients at risk for recurrence correlated immunologic readouts — including expansion of E75-specific CD8+ T cells — with clinical response, and the review was framed around that immunologic-to-clinical correlation (PMID 24896623). A 2016 review in Breast Care traced the clinical development programme of the E75 vaccine in breast cancer across its successive trial phases (PMID 27239173).

More recently, a 2023 report in Cancer Prevention Research described a phase II trial of the nelipepimut-S peptide vaccine conducted in women with ductal carcinoma in situ, extending the study population beyond invasive disease into a pre-invasive setting (PMID 37259799). That trial is the most recent primary study of the peptide on the verified reference list for this entry.

Beyond the agent-specific literature, NeuVax is routinely listed as one example within broader surveys of breast cancer vaccine development. A 2017 review in Frontiers in Endocrinology surveyed breast cancer vaccines and the immunologic insights driving them (PMID 29081765), a 2019 review discussed progress and the recurring obstacles facing breast cancer vaccines as a field (PMID 29732989), and a 2022 review placed vaccine strategies alongside other immunotherapeutic options for breast cancer treatment (PMID 33902424). A common theme across those reviews is that peptide vaccines have been able to generate measurable antigen-specific immune responses while translation into durable clinical benefit has remained the central challenge, a point the 2015 immunological-basis review addressed directly (PMID 26523780).

Tolerability of Nelipepimut-S in Trials: What Studies Report

Reported tolerability information for this peptide comes from the trial literature rather than from any consumer-facing source. The 2014 review reported that the HER2 peptide vaccine had been evaluated for safety alongside its immunologic endpoints in phase I and phase II breast cancer trials and that the vaccine was capable of stimulating expansion of peptide-specific CD8+ T cells in vaccinated patients (PMID 24896623). The 2016 clinical-development review similarly summarised the accumulated trial experience with E75 across its development programme (PMID 27239173), and the 2023 phase II study reported outcomes for nelipepimut-S in a ductal carcinoma in situ population (PMID 37259799). No specific dosing schedule is stated on this page, because the verified sources summarised here are cited at the level of study design and population rather than exact administration schedules.

Regulatory and Research Status

NeuVax has been studied as an investigational agent in clinical trials; it is not a marketed dietary or wellness product, and the reviews cited above discuss breast cancer vaccines as an active but unresolved area of clinical investigation rather than as established standard care (PMID 29732989, PMID 33902424). Eligibility in the trials described also depended on HLA type and HER2 expression, as the 2014 review noted when describing the HLA-A2/A3 restriction of the peptide (PMID 24896623), which is a distinguishing feature of peptide vaccines compared with agents that are not HLA-restricted.

Common Points of Confusion

• NeuVax is not trastuzumab. Trastuzumab is a monoclonal antibody; nelipepimut-S is a short HER2-derived peptide antigen studied as a vaccine with GM-CSF (PMID 24896623).
• NeuVax is not a "research peptide" in the metabolic sense. Its published literature sits entirely within oncology and tumour immunology (PMID 26523780).
• Immune response and clinical outcome are separate endpoints. The reviews on this list discuss the gap between measurable antigen-specific immunity and clinical benefit as the field's main open question (PMID 29081765).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, cancer screening or treatment decision. Nothing here describes how any agent should be obtained, prepared or administered.

References

• The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response (Immunotherapy, 2014)
• Clinical Development of the E75 Vaccine in Breast Cancer (Breast Care, 2016)
• Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ (Cancer Prevention Research, 2023)
• Peptide vaccines in breast cancer: The immunological basis for clinical response (Biotechnology Advances, 2015)
• Breast Cancer Vaccines: New Insights (Frontiers in Endocrinology, 2017)
• Towards Breast Cancer Vaccines, Progress and Challenges (Current Drug Discovery Technologies, 2019)
• Immunotherapy for Breast Cancer Treatment: Current Evidence and Therapeutic Options (Endocrine, Metabolic & Immune Disorders Drug Targets, 2022)